BioNTech CEO Ugur Sahin sells 86K shares
BioNTech’s CEO Ugur Sahin sold 86,000 ordinary shares under a Rule 10b5-1 plan while retaining over 39 million shares indirectly through Medine GmbH.
Rhea-AI Filing Summary
BioNTech SE (BNTX) reported that Chief Executive Officer and major shareholder Ugur Sahin sold a total of 86,000 ordinary shares in mid-September 2026 under a pre-arranged trading plan. He sold 41,000 shares on September 14, 2026 at an average price of 99.4467 per share and 45,000 shares on September 11, 2026 at an average price of 96.9338 per share.
After these sales, an entity associated with him, Medine GmbH, held 39,218,111 ordinary shares indirectly, including 106,721 shares held in trust where Medine GmbH has voting power but not dispositive power. The sales were effected pursuant to a Rule 10b5-1 trading plan established on June 3, 2026.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 86,000 shares
Net Sell
3 txns
Insider
Sahin Ugur
Role
Chief Executive Officer
Sold
86,000 shs ($8.44M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 41,000 | $99.4467 | $4.08M |
| Sale | Ordinary Shares | 45,000 | $96.9338 | $4.36M |
| holding | Ordinary Shares F1 | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 602,209 shares (Direct);
Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)
Footnotes (1)
- F1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.
Key Figures
Shares sold on September 14, 2026: 41,000 ordinary shares
Shares sold on September 11, 2026: 45,000 ordinary shares
Total shares sold in reported period: 86,000 ordinary shares
+3 more
6 metrics
Shares sold on September 14, 2026
41,000 ordinary shares
Sale by Ugur Sahin at an average price of 99.4467 per share
Shares sold on September 11, 2026
45,000 ordinary shares
Sale by Ugur Sahin at an average price of 96.9338 per share
Total shares sold in reported period
86,000 ordinary shares
Combined sales on September 11 and September 14, 2026
Indirect holdings through Medine GmbH
39,218,111 ordinary shares
Indirectly held as of September 11, 2026 and may be deemed beneficially owned
Shares held in trust
106,721 ordinary shares
Held for the benefit of an individual; Medine GmbH has voting but not dispositive power
Rule 10b5-1 plan adoption date
June 3, 2026
Date Ugur Sahin established the trading plan used for these sales
Key Terms
Rule 10b5-1 trading plan, beneficially own, voting power, dispositive power
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
beneficially own financial
"The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH."
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
voting power financial
"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust."
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.
dispositive power financial
"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust."
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BioNTech (BNTX) report for Ugur Sahin?
The filing reports that Ugur Sahin sold 86,000 ordinary shares of BioNTech SE in two transactions on September 11 and September 14, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.
What is Ugur Sahin’s role at BioNTech (BNTX) mentioned in this Form 4?
The reporting person, Ugur Sahin, is identified as Chief Executive Officer of BioNTech SE and a holder of more than ten percent of the company’s shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
